|Daily Range||$2.11 - $2.17|
|52-Week Range||$1.91 - $3.10|
|Dividend (Yield)||$0.00 (0.0%)|
|Average Daily Volume||279,956|
|Current FY EPS||-$0.47|
How do you think ARQL
will perform against the market?
Top ARQL Bull/Bear Pitches
NetscribeHealthC (< 20)
Submitted March 12, 2007
ArQule is developing a portfolio of proprietary small molecule drugs to treat cancer. The company’s technology platform includes the Activated Checkpoint Therapy (ACT) program, which seeks to harness … More
Submitted February 19, 2007
Carefully watching this stock, hoping for some positive news.
News & Commentary
ArQule, Inc. (ARQL) Description
A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics. Website: http://www.arqule.com/